Drug Trial Radar · NCT06046274
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
Last checked: Nov 19, 2026Latest source record: Apr 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Oct 1, 2023
Primary completion
Apr 1, 2028
Study completion Jun 1, 2028
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn about the bispecific antibody, acasunlimab (also known as GEN1046) in combination with the cancer drug pembrolizumab for treatment of participants with incurable endometrial cancer (cancer of the womb). The main questions the study aims to answer are: * How well acasunlimab in combination with pembrolizumab works against endometrial cancer * What are the potential side effects participants may experience when they are treated with acasunlimab in combination with pembrolizumab Participants will receive both acasunlimab and pembrolizumab. All participants will receive active drug; no one will receive placebo. participants will participate in 1 of 2 cohorts. A participant will receive study treatment up to a maximum of 24 months. The study duration (including screening, treatment, and follow-up) for each participant will be about 39 months.
Conditions
- Advanced Endometrial Cancer
Interventions
PembrolizumabBiological
Pembrolizumab intravenous (IV) infusion
AcasunlimabBiological
Acasunlimab IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to 4 years
Locations
29 sites in 6 countries. Site status is shown where the registry gives one.
Orlando Health Cancer Institute
Orlando, Florida
Rudgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Grand Hospital de Charleroi
Charleroi, Belgium
Universitair Ziekenhuis Ghent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Aalborg University Hospital
Aalborg, Denmark
Rigshospitalet
Copenhagen, Denmark
Odense Universitetshospital
Odense, Denmark
AOU Policlinico Sant'Orsola Malpighi IRCCS
Bologna, Italy
IRCCS Istituto Europeo di Oncologia IEO
Milan, Italy
Fondazione G. Pascale
Naples, Italy
IRCCS Policlinico Universitario Agostino Gemelli
Roma, Italy
Ospedale Mauriziano Umberto I
Torino, Italy
Keimyung University Dongsan Medical Center
Daegu, South Korea
National Cancer Center Korea
Goyang-si, South Korea
Pusan National University
Pusan, South Korea
Seoul National University Bundang Hospital
Seongnam, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System|Division of Infectious Diseases
Seoul, South Korea
Hospital Universitari Vall d'Hebron
Barcelona, Spain
ICO Girona
Girona, Spain
Clínica Universidad de Navarra
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Fundacion Jiménez Díaz
Madrid, Spain
Clínica Universidad de Navarra
Pamplona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.